Correction to: Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications

Affiliations

¹ The Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Windmill Road, Oxford, OX3 7LD, UK. peter.taylor@kennedy.ox.ac.uk.
² Department of Dermatology and Allergy, University of Bonn, Bonn, Germany.
³ Christine Kühne-Center for Allergy Research and Education, Davos, Switzerland.
⁴ Department of Internal Medicine and Rheumatology, Schlosspark-Klinik Charité, University Medicine Berlin, Berlin, Germany.
⁵ Clinical Immunology, Hannover Medical School, Hannover, Germany.
⁶ Centre for Rheumatic Diseases, King's College London, London, UK.
⁷ Eli Lilly and Company, Indianapolis, IN, USA.
⁸ Department of Dermatology and Allergology, Ludwig Maximilian University of Munich, Munich, Germany.
⁹ Department of Dermatology, Vrije Universiteit Brussel, Universitair Ziekenhuis Brussel, Brussels, Belgium.

Published Erratum

Peter C Taylor et al. Adv Ther. 2025 Sep.

. 2025 Sep;42(9):4717-4719.

doi: 10.1007/s12325-025-03244-1.

¹ The Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Windmill Road, Oxford, OX3 7LD, UK. peter.taylor@kennedy.ox.ac.uk.
² Department of Dermatology and Allergy, University of Bonn, Bonn, Germany.
³ Christine Kühne-Center for Allergy Research and Education, Davos, Switzerland.
⁴ Department of Internal Medicine and Rheumatology, Schlosspark-Klinik Charité, University Medicine Berlin, Berlin, Germany.
⁵ Clinical Immunology, Hannover Medical School, Hannover, Germany.
⁶ Centre for Rheumatic Diseases, King's College London, London, UK.
⁷ Eli Lilly and Company, Indianapolis, IN, USA.
⁸ Department of Dermatology and Allergology, Ludwig Maximilian University of Munich, Munich, Germany.
⁹ Department of Dermatology, Vrije Universiteit Brussel, Universitair Ziekenhuis Brussel, Brussels, Belgium.

No abstract available

Erratum for

Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications.
Taylor PC, Bieber T, Alten R, Witte T, Galloway J, Deberdt W, Issa M, Haladyj E, De La Torre I, Grond S, Wollenberg A. Taylor PC, et al. Adv Ther. 2023 Apr;40(4):1867-1883. doi: 10.1007/s12325-023-02445-w. Epub 2023 Feb 20. Adv Ther. 2023. PMID: 36802049 Free PMC article. Clinical Trial.